Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) generated frequent news as a biopharmaceutical company focused on developing new solid tumor cancer therapies and as the vehicle for a significant reverse merger with TuHURA Biosciences, Inc. Company press releases describe Kintara as located in San Diego, California and dedicated to novel cancer therapies for patients with unmet medical needs, with a lead program centered on REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
The KTRA news flow prominently features updates on REM-001 Therapy, including details of an open-label CMBC study, prior Phase 2/3 clinical experience, and the role of a Small Business Innovation Research grant from the National Institutes of Health in supporting study costs. These items provide context on the company’s proprietary late-stage photodynamic therapy platform, which combines a laser light source, a light delivery device, and the REM-001 drug product.
Another major theme in Kintara’s news coverage is its merger with TuHURA Biosciences, Inc. Articles outline the definitive merger agreement, stockholder meetings, voting instructions, and the strategic rationale for combining Kintara’s oncology assets with TuHURA’s Phase 3 registration-stage immuno-oncology programs. Releases discuss the expected ownership structure of the combined company, the planned corporate name change to TuHURA Biosciences, Inc., and the transition of trading to the Nasdaq Capital Market under the symbol HURA.
News items also detail corporate actions tied to the merger, including the approval and implementation of a 1-for-35 reverse stock split and the establishment of Contingent Value Rights (CVRs) to provide potential additional share consideration to Kintara stockholders upon achievement of specified REM-001 study milestones. Additional coverage includes reminders to stockholders to vote on key proposals, adjournments and reconvening of special meetings, and fiscal year financial results accompanied by corporate updates.
For readers following KTRA historically, this news archive offers insight into Kintara’s oncology development efforts, its financial and strategic decisions, and the sequence of events that led to the transformation of the Kintara listing into TuHURA Biosciences, Inc. under the HURA ticker. Regular review of these releases helps clarify how the company’s clinical programs and corporate structure evolved over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kintara Therapeutics (Nasdaq: KTRA) has announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The company will present data on its investigational drug VAL-083, focused on treating RELA fusion-positive ependymoma and recurrent glioblastoma. Two abstracts will be shared: one detailing case studies of VAL-083 in patients with ependymoma and glioma under an expanded access program, and another highlighting findings from 24 recurrent glioblastoma patients. Kintara is dedicated to developing innovative cancer therapies, with VAL-083 currently being advanced in the GBM AGILE registrational study.
Kintara Therapeutics (Nasdaq: KTRA) announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 14-19 in Orlando. The company will present two posters focused on its lead program, VAL-083, aimed at treating recurrent glioblastoma. The presentations, on April 17, will cover case reports of RELA fusion-positive ependymoma and VAL-083’s application in glioblastoma patients under expanded access. Kintara, based in San Diego, is dedicated to developing novel cancer therapies to address significant medical needs.
Kintara Therapeutics, Inc. (NASDAQ: KTRA) announced its participation in two significant conferences in March 2023. At the 35th Annual ROTH Conference in Dana Point, CA, CEO Robert E. Hoffman will provide a corporate update on March 13 at 10:30 AM PT. Concurrently, at the 4th Annual Glioblastoma Drug Development Summit in Boston, MA, Dr. Dennis Brown and Greg Johnson will discuss Kintara's VAL-083 program for glioblastoma on March 15 at 4:00 PM ET. Kintara focuses on developing innovative cancer therapies, specifically VAL-083 for glioblastoma and REM-001 Therapy for cutaneous metastatic breast cancer.